Clinical phase I study with one-hour paclitaxel infusion

Annals of Oncology

Volumn 9, Issue 5, 1998, Pages 569-572

  Mross, K ^a   Hauns, B ^a   Haring B ^a   Bauknecht, T ^b   Meerpohl, H G ^c   Unger, C ^a   Maier Lenz, H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c St Vincentius Hospital Karlsruhe   (Germany)

Author keywords

Paclitaxel (Taxol ); Phase I study; Toxicity

Indexed keywords

PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FATIGUE; FEMALE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUROPATHY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031840338     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008217429971     Document Type: Article

References (16)

1. DeBrabander M, Geuens G, Nuydens R. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci 1981; 78: 5608-12.
2. Spencer CM, Faulds D. Pacclitaxel - a review of ist pharmacodynamic and pharmacokinetic properties and therapeutical potential in the treatment of cancer. Drugs 1994; 48: 794-847.
3. Eisenhauer EA, ten Bokkel Huinink H, Swenerton KD et al. European-Canadian randomized trial of taxol in relapsed ovarian cancer: High vs. low-dose and long vs. short infusion. J Clin Oncol 1994; 12: 2654-66.
4. Slevin ML, Clark PI, Joel SP. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333-40.
5. Weiss RB, Donehower RC, Wiernik PH et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8.
6. Hainsworth JD, Greco FA. Paclitaxel administered by one-hour infusion: Preliminary results of a phase I-II trial comparing two schedules. Cancer 1994; 74: 1377-82.
7. Grem JL, Tutsch KD, Simon KJ et al. Phase I study of taxol administered as a short i.v. infusion daily for five days. Cancer Treat Rep 1987; 71: 1179-84.
8. Lokich J, Anderson N, Bern M. Multi-day fractionated administration schedule for paclitaxel. Ann Oncol 1995; 6: 883-5.
9. Wilson WH, Berg SL, Bryant G et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I-II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621-9.
10. Spriggs DR, Tondini C. Taxol administered as a 120-hour infusion. Invest New Drugs 1992; 10: 275-8.
11. Cagnoni PJ, Stemmer SM, Matthes S et al. Phase I trial of high-dose paclitaxel (Taxol), cyclophosphamide (CPA) and cisplatin (CDDP) with autologous hematopoietic progenitor cell (AHPC) rescue. Proc ASCO 1995; 14: 477 (no. 1548).
12. Woodcock DM, Jefferson S, Linsenmeyer ME et al. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990; 50: 4199-204.
13. Gianni L, Kearns CM, Giani A. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-90.
14. Huizing MT, Keung AC, Rosing H. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11: 2127-35.
15. Gennari A, Salvadori B,Tagnoni A, Conte PE. Rapid intravenous premedication with dexamethosone prevents hypersensitivity reactions with paclitaxel. Ann Oncol 1996; 7: 978-9.
16. Greco F, Hainsworth JD. Paclitaxel (one-hour infusion) plus carboplatin in the treatment of advanced NSCLC: Results of a multicenter phase II trial. Semin Oncol 1997; 4 (Suppl 12), 24: 14-7.